Mitoxantrone has 9 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Fingolimod, Fingolimod Hydrochloride, Sofosbuvir, Velpatasvir, And Voxilaprevir. Patients taking Mitoxantrone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 9
- Major
- 3
- Moderate
- 6
Major (3)
- Mitoxantrone + Fingolimod— When switching from mitoxantrone to fingolimod, consider duration and mode of action to avoid unintended additive immuno…
- Mitoxantrone + Fingolimod Hydrochloride— Prolonged immune effects drug requiring consideration of duration and mode of action to avoid additive immunosuppressive…
- Mitoxantrone + Sofosbuvir, Velpatasvir, And Voxilaprevir— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
Moderate (6)
- Mitoxantrone + Eltrombopag— BCRP substrate; eltrombopag may increase exposure. Monitor closely for signs of excessive exposure.
- Mitoxantrone + Eltrombopag Olamine— BCRP substrate; monitor for excessive exposure and consider dose reduction if appropriate.
- Mitoxantrone + Fingolimod Lauryl Sulfate— Prolonged immune effects drug; consider duration and mode of action to avoid additive immunosuppressive effects when swi…
- Mitoxantrone + Ocrelizumab— Concomitant use may cause additive immunosuppressive effects. Consider duration and mode of action when switching from m…
- Mitoxantrone + Ocrelizumab And Hyaluronidase— Concomitant use may increase risk of additive immunosuppressive effects due to prolonged immune effects of mitoxantrone.…
- Mitoxantrone + Teriflunomide— Teriflunomide may increase exposure of mitoxantrone. Consider reducing dose and monitor patients closely.